Dr Josh Gardner

Post-doctoral research associate studying immune-mediated adverse drug reactions to cystic fibrosis therapies. @Immunopharm @pandtUoL

[Inst of Systems, Molecular & Integrative Biology @LivUniISMIB]

Drug safety experts in Liverpool and China plan joint research centre 💊

➡️https://t.co/x39Qld9bb8

#drugsafety | #TeamLivUni

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Congratulations @josh_gardner95 for being awarded the BSI career enhancing grant! 🔬🧪🥼

[Dr Josh Gardner @josh_gardner95]

Great to finally see this work published - revealing unexpected and widespread T-cell cross-reactivity associated with the ChAdOx1 vaccine 💉 @NIHRresearch

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Have a read of our most recent paper by @josh_gardner95, @SophieGrice5 and Luisa Hering published in @Nature_NPJ Vaccines looking at the identification of cross reactive T cell responses in adenovirus based COVID-19 vaccines

https://t.co/O7kegNrnQ4

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Read our latest paper from @josh_gardner95 published in @ClinExpAllergy on the application of glycolysis to measure and detect the activation of drug-specifc T-cells.
https://t.co/1QD78g8sCB

[Naisbitt Hypersensitivity Group @ImmunoPharm]

This afternoon our Post Doc @josh_gardner95 presented a talk to the @EAACI_HQ Drug Hypersensitivity Meeting in Verona on how Glycolytic switching can be used as an early marker of vancomycin-specific T-cell activation. Great talk Josh! 🇮🇹🦠

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Today the team is attending @pandtuol’s Winter Away Day, with Dr @josh_gardner95 presenting some of the work we do in the Immuno-Pharmacology group 💊🩸🧬💉🦠@LivUniISMIB_PDS @LivUniISMIB

[Dr Josh Gardner @josh_gardner95]

@Copple_lab @ImmunoPharm @pandtuol @CDSS_Liverpool Thanks Ian!

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Congratulations to @josh_gardner95 for passing his PhD viva yesterday! Well done for years of hard work and dedication particularly through the pandemic Dr Gardner! 👨🏼‍🎓 @pandtuol @CDSS_Liverpool

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Extra special congratulations to @Dr_pauljth10 and @josh_gardner95 for winning Best Oral and Poster Presentations respectively.

[Naisbitt Hypersensitivity Group @ImmunoPharm]

A great week had at #SOT2022 meeting in San Diego by our group members @Dr_pauljth10 and @josh_gardner95 both presenting their posters on our work! #SOToxicology

[Naisbitt Hypersensitivity Group @ImmunoPharm]

We’ve got that friday feeling with our group’s latest paper investigating the immunogenicity of teicoplanin having just been published!

Congratulations to @josh_gardner95 on his first lead author paper!

https://t.co/7UNPgyX2eH

[Toxicological Sciences @ToxSci]

Vancomycin causes Drug rash with eosinophilia with systemic symptoms (DRESS) via priming of naïve T cells from donors expressing HLA-A*32:01 #pharmacogenomics #OpenAccess @ImmunoPharm https://t.co/JisXQr6xPJ

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Hot off the press; this lunchtime take some time out to read our latest paper in @ToxSci focused on T cell mediated responses to the glycopeptide antibiotic vancomycin lead by @MondayOgese, Dr Adam Lister and @josh_gardner95 https://t.co/ryWbBdDJTQ

[David Perkins @DavidJPerkins]

@jitcancer @SerateAli @AOlssonBrown I’d also like to congratulate authors 3 @josh_gardner95 and 4 @Dr_pauljth10

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Congratulations to @kareena_adair @SerateAli @josh_gardner95 @jkanoot @MondayOgese @Dr_pauljth10 from the Naisbitt group. Hard work over the pandemic has paid off!

[Toxicological Sciences @ToxSci]

#ToxSpotlight shines on Ph.D. student Sean Hammond of the University of Liverpool! Sean is first author of Jan 2021 paper on effector role of drug- and metabolite-specific T cells in tolvaptan liver injury.

Meet Sean: https://t.co/0zhkOjL8Ph

Paper: https://t.co/7akR4SzuME

[Naisbitt Hypersensitivity Group @ImmunoPharm]

“The UK is one step closer to providing a safe and effective vaccine”

Proud to see the director of our centre, @MPUoL leading the way in the fight against the virus. @CDSS_Liverpool @JamesLine14 @_AndrewOwen_

[Naisbitt Hypersensitivity Group @ImmunoPharm]

We have just published In the @J_Immunol ! Great news for a Friday afternoon.

Our team present a detailed analysis of clozapine-responsive human T-cells.

Have a read https://t.co/Z4yCzygEFt

Enjoy your weekend folks!

#drugallergy #tcells #clozapine

[Naisbitt Hypersensitivity Group @ImmunoPharm]

Over the last few months our CL2 laboratory has received over 400 COVID-LIV samples, processed over 250 blood samples and stored nearly 1300 vials! A big thank you and congratulations to everyone who has made all this possible during these difficult times. Keep up the great work.

[Naisbitt Hypersensitivity Group @ImmunoPharm]

We know it’s Tuesday and the weather is grim, but we have some good news! @aruntailor @xl_meng @kareenaadairrr have just published a new article in @ToxSci !

Cheer yourself up with some coffee and great science 🧪😉

https://t.co/GlGm1jI1vT